Pipeline

Pre-Clinical

Clinical Preparation

Phase I/II

Collaboration

Acute Myeloid Leukemia (“AML”): Annamycin

Annamycin
Annamycin + WP1066

Brain Tumors: WP1066 & WP1122

WP1066 - Glioblastoma, melanoma metastasized to the brain
WP1066 - Diffuse intrinsic pontine gliomas (children)
WP1122 - Glioblastoma
WP1122 + Avastin - Glioblastoma

Pancreatic Cancer: WP1066 & WP1122

WP1066/WP1732
WP1122/1234 - Pancreatic cancer

Cutaneous T-Cell Lymphoma (“CTLC”): WP1220

WP1220 - Cutaneous T-Cell Lymphoma

Ocular Tumors: WP1066

WP1066 - Ocular tumors

Next Generation Anthracycline

Immune/Transcription Modulators

Metabolism/Glycosylation Inhibitors

Combination

Anticipated Milestones

NEXT GENERATION ANTHRACYCLINE - ANNAMYCIN ANTICIPATED MILESTONES
Clinical Trials - Complete cohort of 150 mg/m2 - prior trial recommended Phase II dose (RP2D)
Announcement of initial clinical data for Annamycin trial
Announcement of RP2D for Poland Trial
Poland clinical trial (MB-105) begins Phase II
Approach FDA on U.S. trial (MB-104) on dose expansion using Poland trial data
Announce additional clinical research in lung and metastatic lung cancers
POTENTIAL TIMEFRAME
Accomplished and ongoing 2019
Accomplished and ongoing 2019
2020
2020
2020 (Fast Track Approved)
2020
IMMUNE/TRANSCRIPTION MODULATOR - WP1066 ANTICIPATED MILESTONES
Clinical Trials WP 1066 - Announcement of initial clinical data from WP1066 clinician sponsored trial
Phase 1 surgical cohort begins
Transfer clinician sponsored trial WP1066 IND to Moleculin
Emory Physician Led Pediatric Medulloblastoma Trial begins
Announcement of further benefits of our sponsored research agreement with MD Anderson
Clinical Trial WP1220 - Announce filing and approval of CTA for WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL)
Assess WP1220 initial patient data
IND for WP1732 submitted
Dose first patient in Phase I trial for WP1732
Announce further preclinical research results on WP1066 family
POTENTIAL TIMEFRAME
2019
2020
Second Half of 2019
Second Half of 2019
Accomplished and Ongoing into 2019
Accomplished
Q4-2019
2020
2020
Accomplished and ongoing 2019
METABOLISM/GLYCOSYLATION INHIBITOR ANTICIPATED MILESTONES
Begin preclinical work on WP1122
Complete formulation and begin manufacture of drug for trial
File IND for WP1122
POTENTIAL TIMEFRAME
Accomplished
First Half of 2020
2020
GENERAL CLINICAL ANTICIPATED MILESTONES
Announce a fourth approved clinical trial
Announce a fifth approved clinical trial
POTENTIAL TIMEFRAME
Accomplished
2019

Pipeline

Milestones